JR
Therapeutic Areas
ONL Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ONL1204 | Acute Primary Angle-Closure Glaucoma (APACG) | Phase 2 |
| ONL1204 (Preclinical) | Retinal Detachment | Preclinical |
| Fas Inhibition Platform | Geographic Atrophy (AMD) | Preclinical |
| Drug | Indication | Phase |
|---|---|---|
| ONL1204 | Acute Primary Angle-Closure Glaucoma (APACG) | Phase 2 |
| ONL1204 (Preclinical) | Retinal Detachment | Preclinical |
| Fas Inhibition Platform | Geographic Atrophy (AMD) | Preclinical |